Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enhances Johnson & Johnson's MedTech business, opening new opportunities in the high-growth heart failure device market. Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4% adjusted operational revenue growth.
J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, R&D investment, growth outlook, state of the company's talc settlement, and more.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago.
Johnson & Johnson stock rises on Q3 sales beat and guidance raise
Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance.
J&J lifts profit and sales forecasts, beats Wall Street expectations
Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15.
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share (EPS) of $2.21 and revenue of $22.16 billion.
Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth
Johnson & Johnson's Q3 2024 earnings report will highlight its MedTech division, driven by strategic acquisitions and R&D investments in cardiovascular and orthopedic solutions. Despite lagging behind the S&P in price growth, JNJ offers a solid income investment with a 3.09% dividend yield and steady financials. Risks include short-term costs from acquisitions, supply chain issues in the Vision division, and external pressures like currency fluctuations and competition.
What Trends Will Drive Johnson & Johnson's Q3 Results?
Johnson & Johnson stock (NYSE: JNJ) will report its Q3 2024 results on Tuesday, October 15. We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus estimates of $22.1 billion and $2.19, respectively.
What You Need to Know Ahead of Johnson & Johnson's Earnings
Johnson & Johnson (JNJ) reports earnings Tuesday morning for the third quarter, with analysts expecting the company's revenue and profit to rise year-on-year.
J&J talc bankruptcy stays in Texas despite 'forum-shopping" opposition
A Johnson & Johnson subsidiary can pursue its third attempt to resolve tens of thousands of lawsuits alleging its talc products caused cancer in a Texas bankruptcy court, a judge ruled on Thursday, allowing the company to avoid a venue that shot down its two previous efforts.
